Oral Multiple Sclerosis Drugs Inhibit the In vitro Growth of Epsilon Toxin Producing Gut Bacterium, Clostridium perfringens

about

Gut-CNS-Axis as Possibility to Modulate Inflammatory Disease Activity-Implications for Multiple Sclerosis

P2860

Q39434933-B2AFB158-EA1D-4D56-B048-60D4FD85D5C1

P2860

Oral Multiple Sclerosis Drugs Inhibit the In vitro Growth of Epsilon Toxin Producing Gut Bacterium, Clostridium perfringens

Item

http://www.wikidata.org/entity/Q28818329

description

2017 nî lūn-bûn

@nan

2017 թուականին հրատարակուած գիտական յօդուած

@hyw

2017 թվականին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Oral Multiple Sclerosis Drugs ...... erium, Clostridium perfringens

@ast

Oral Multiple Sclerosis Drugs ...... erium, Clostridium perfringens

@en

type

Item

label

Oral Multiple Sclerosis Drugs ...... erium, Clostridium perfringens

@ast

Oral Multiple Sclerosis Drugs ...... erium, Clostridium perfringens

@en

prefLabel

Oral Multiple Sclerosis Drugs ...... erium, Clostridium perfringens

@ast

Oral Multiple Sclerosis Drugs ...... erium, Clostridium perfringens

@en

P1476

Oral Multiple Sclerosis Drugs ...... erium, Clostridium perfringens

@en

P2093

Kareem R Rumah

http://www.w3.org/2001/XMLSchema#string

Timothy K Vartanian

http://www.w3.org/2001/XMLSchema#string

Vincent A Fischetti

http://www.w3.org/2001/XMLSchema#string

P2860

The Myelin and Lymphocyte Protein MAL Is Required for Binding and Activity of Clostridium perfringens ε-Toxin

Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion

On dihydroorotate dehydrogenases and their inhibitors and uses

Epsilon toxin: a fascinating pore-forming toxin.

Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study.

Gambogic acid inhibits proliferation of human lung carcinoma SPC-A1 cells in vivo and in vitro and represses telomerase activity and telomerase reverse transcriptase mRNA expression in the cells.

Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite.

Sphingoid long chain bases prevent lung infection by Pseudomonas aeruginosa.

Potency of Michael reaction acceptors as inducers of enzymes that protect against carcinogenesis depends on their reactivity with sulfhydryl groups

Isolation of Clostridium perfringens type B in an individual at first clinical presentation of multiple sclerosis provides clues for environmental triggers of the disease.

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FCIMB.2017.00011

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28180112

http://www.w3.org/2001/XMLSchema#string

P932

5263136

http://www.w3.org/2001/XMLSchema#string

Oral Multiple Sclerosis Drugs Inhibit the In vitro Growth of Epsilon Toxin Producing Gut Bacterium, Clostridium perfringens

about

P2860

P2860

Oral Multiple Sclerosis Drugs Inhibit the In vitro Growth of Epsilon Toxin Producing Gut Bacterium, Clostridium perfringens

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P932